Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis

BACKGROUND: 25% of breast cancer patients suffer from aggressive HER2-positive tumours that are characterised by overexpression of the HER2 protein or by its increased tyrosine kinase activity. Herceptin is a major drug used to treat HER2 positive breast cancer. Understanding the molecular events th...

Descripción completa

Detalles Bibliográficos
Autores principales: Buiga, Petronela, Elson, Ari, Tabernero, Lydia, Schwartz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907139/
https://www.ncbi.nlm.nih.gov/pubmed/29671404
http://dx.doi.org/10.1186/s12918-018-0534-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907139/
https://www.ncbi.nlm.nih.gov/pubmed/29671404
http://dx.doi.org/10.1186/s12918-018-0534-5

Ejemplares similares